---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Dosage"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Dosage. Topics: Single 25 mg dose in COMP005 and two fixed doses in COMP006, Dose response in the phase 2b trial, Retreatment in Parts B and C of the phase 3 trials, Dosing the company intends to seek in labeling, and 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/dosage"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Single 25 mg dose in COMP005 and two fixed doses in COMP006

> “Pivotal trial 1 (COMP005) (n=258): a single dose (25mg) monotherapy compared with placebo.”
> “Pivotal trial 2 (COMP006) (n=581): a fixed repeat dose monotherapy using three dose arms: 25mg, 10mg and 1mg.”
> “This trial is designed to investigate whether a second dose can increase therapeutic response.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint.”

Source: [COMPASS Pathways Form 8-K COMP006 topline (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000007/cmps-20260217.htm)

<a id="topic-2.1.2.10.1-2"></a>

### Dose response in the phase 2b trial

> “psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects.”

Source: [Goodwin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36322843/)

<a id="topic-2.1.2.10.1-3"></a>

### Retreatment in Parts B and C of the phase 3 trials

> “During Part B, based on pre-specified criteria, participants were eligible either for a second administration of the treatment to which they were randomized or to resume antidepressants.”
> “During Part B, 70% of participants in the 25mg arm and 53% of participants in the placebo arm received a second administration.”

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

> “Re-dosing for non-remitters from Part A or Part B could occur several weeks after transition to Part B or Part C, respectively, due to scheduling requirements.”
> “COMP360 25mg treatment (one dose only after relapse or for non-remitters from Part B)”
> “Findings provide further evidence of notable reduction in MADRS and prolonged durability that can be experienced with just two or three doses of 25mg COMP360 within a year”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.10.1-4"></a>

### Dosing the company intends to seek in labeling

> “As we have said always, what we would envisage and target is after one or two initial administrations, that then there is the provision for episodic dosing per physician decision.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

> “Label has not been determined as COMP360 is not yet approved by the FDA”

Source: [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf)

<a id="topic-2.1.2.10.1-5"></a>

### Capsule strength and count in the phase 1 study

> “The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).”

Source: [Rucker et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8801675/)

<a id="topic-2.1.2.10.1-6"></a>

### Regulatory expectations for evaluating repeat dosing

> “Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.”
> “The most informative clinical trial design would incorporate blinded long-term follow-up (typically 12 months) with prespecified criteria for retreatment.”

Source: [FDA psychedelic drugs guidance (2026)](https://www.fda.gov/media/169694/download)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
